Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KDM6B | O15054 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19611328 | 0.82 | KDM4C (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL188821 | 0.82 | KDM4C (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL662028 | 0.82 | SIRT3 (0.58) | CA12CA1CA2CA9CA14 | |
| SCHEMBL9142180 | 0.81 | SIRT3 (0.56) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL7084808 | 0.81 | SIRT3 (0.56) | CA12CA1CA2CA9CA14 | |
| Acetone SCHEMBL5667714 | 0.78 | SIRT3 (0.58) | CA12CA1CA2CA9CA14 | |
| Acetone SCHEMBL2032550 | 0.78 | KDM4C (0.54) | CA12CA1CA2CA9CA14 | |
| Acetone SCHEMBL15923153 | 0.77 | KDM4C (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL8067971 | 0.76 | KDM4E (0.52) | TDP1SIRT3KDM4CKDM4EKDM6B | |
| SCHEMBL12830011 | 0.73 | KDM4C (0.68) | TDP1KDM4CKDM4EKDM6BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364690-A | Novel radiolabeled CXCR4 targeting compounds for diagnosis and therapy | 省卫生服务机构 | 2022-04-15 | — | — | CN | disclosed |
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1140203-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7179446-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1423152-A4 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2006-12-27 | — | — | EP | disclosed |
| US-7138104-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-7090828-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-7052673-B2 | Pharmaceuticals for the imaging of angiogenic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| WO-2001097861-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| US-6322770-B1 | FOR DIAGNOSIS AND TREATMENT OF CANCER, IMAGING TUMORS, MONITORING THERAPEUTIC ANGIOGENESIS TREATMENT AND DESTRUCTION OF NEW ANGIOGENIC VASCULATURE; COMPRISED OF TARGETING MOIETY THAT BINDS TO RECEPTOR AND RADIOISOTOPE | DUPONT PHARMACEUTICALS COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140864-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1068224-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035887-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARM CO (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999058162-A2 | PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |